Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jan;33(1):35-41.
doi: 10.1016/j.tips.2011.09.004. Epub 2011 Oct 25.

Interleukin-15 biology and its therapeutic implications in cancer

Jason C Steel  1 , Thomas A Waldmann, John C Morris
Affiliations
Review

Interleukin-15 biology and its therapeutic implications in cancer

Jason C Steel et al. Trends Pharmacol Sci. 2012 Jan.

Abstract

Cancer immunotherapy is designed to stimulate the immune system to reject and destroy tumors. Recently, interleukin-15 (IL-15), a member of the four α-helix bundle family of cytokines, has emerged as a candidate immunomodulator for the treatment of cancer. IL-15 acts through its specific receptor, IL-15Rα, which is expressed on antigen-presenting dendritic cells, monocytes and macrophages. IL-15 exhibits broad activity and induces the differentiation and proliferation of T, B and natural killer (NK) cells. It also enhances the cytolytic activity of CD8(+) T cells and induces long-lasting antigen-experienced CD8(+)CD44(hi) memory T cells. IL-15 stimulates differentiation and immunoglobulin synthesis by B cells and induces maturation of dendritic cells. It does not stimulate immunosuppressive T regulatory cells (Tregs). Thus, boosting IL-15 activity could enhance innate and specific immunity and fight tumors. Here we review aspects of IL-15 biology that make it a promising agent for anticancer therapy. We also discuss preclinical models in which IL-15 has demonstrated antitumor activity and highlight ongoing clinical trials of IL-15 in patients with cancer and HIV infection.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Interleukin-15 genomic organization and gene expression
IL-15 is encoded by a 34 kb region on human chromosome 4q31. The IL-15 gene is made up of nine (1–8 and 4A) exons and eight introns of which 4 exons (5 through 8) code for the mature protein. There are 2 isoforms of IL-15 mRNA that differ in the length of their signal peptides. The originally identified form consisted of a 316 bp 5’-untranslated region (UTR), a 486 bp coding sequence, and a 400 bp 3’UTR that is translated into an IL-15 precursor protein with a long signal peptide (IL-15LSP) of 48 amino acids. The long signal peptide is encoded within exons 3–5. The other isoform has a short signal peptide of 21 amino acids (IL-15SSP) encoded by exons 4A and 5. Both isoforms produce the same mature protein; however, the two differ in that they have distinct intracellular trafficking. IL-15LSP is targeted to the Golgi apparatus, early endosomes and the endoplasmic reticulum secretory pathway where it is complex with IL15Rα. IL-15SSP is not secreted and appears to be restricted to the cytoplasm and nucleus.
Figure 2
Figure 2. Interaction of interleukin-2 (IL-2) with its receptor (IL-2R) contrasted to that of IL-15 and its receptor (IL-15R)
The high affinity IL-2R is a heterotrimeric complex composed of the common cytokine receptor gamma subunit (γc), a beta subunit (IL-2R/IL-15Rβ) that is also shared with the IL-15 receptor (IL-15R), and a private alpha subunit (IL-2Rα). All three subunits are expressed on activated NK, T and other immune cells. Receptor specificity is conferred by the alpha subunit of each cytokine (IL-2Rα or IL-15Rα) and signal transduction is mediated through IL-2R/IL-15Rβ and yc. For IL-2, all three subunits (IL-2Rα, IL-2R/IL-15Rβ, and γc) are expressed by the same cell and as a complex directly bind soluble IL-2. In contrast, the interaction of IL-15 with its receptor is more complex. Little IL-15 appears to be expressed in a free soluble state. Rather, IL-15 is presented in trans pre-associated with IL-15Rα by antigen-presenting cells to the IL-2R/IL-15Rβ and γc receptor subunits expressed on NK and T cells. IL-15 is expressed by monocytes/macrophages and dendritic cells and is stabilized by being associated with IL-15Rα in the endosomal-Golgi apparatus. The IL-15/IL-15Rα complex is secreted and expressed on the surface of monocytes and dendritic cells to present IL-15 to the IL-2R/IL-15Rβ and γc subunits expressed on NK and CD8+ T cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kantoff PW, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2010;363(5):411–422. - PubMed
    1. Hodi FS, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N. Engl. J. Med. 2010;363(8):711–723. - PMC - PubMed
    1. Mocellin S, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2010;102(7):493–501. - PubMed
    1. Tarhini AA, Agarwala SS. Interleukin-2 for the treatment of melanoma. Curr. Opin. Investig. Drugs. 2005;6(12):1234–1239. - PubMed
    1. Burton JD, et al. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA. 1994;91(11):4935–4939. - PMC - PubMed

Publication types

-